香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部份 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 Sirnaomics Ltd. 聖 諾 醫 藥 * （ 於開曼群島註冊成立之有限公司） （股份代號：2257） 自願性公告 業務更新 – 1 – 本 公 告 乃 由 本 公 司 自 願 作 出 。 概 不 保 證 本 公 司 將 能 成 功 開 發 或 最 終 將 STP 707成功商業化。本公司股東及潛在投資者於買賣本公司股份時應審慎 及謹慎行事。 承董事會命 Sirnaomics Ltd. 主席兼執行董事 潘洪輝 香港，2025年12月22日 於 本 公 告 日 期 ， 董 事 會 包 括 執 行 董 事 潘 洪 輝 博 士 、 非 執 行 董 事 歐 陽 雲 龍 先 生 及殷 惠 軍 博 士 ，以 及 獨 立 非執 行 董 事 王 宇山 先 生 、 ...

Group 1 - Hong Kong pharmaceutical stocks experienced a general decline, with notable drops in share prices [1] - Gilead Sciences-B (01672.HK) fell by 11.02%, trading at HKD 12.92 [1] - Saint Noble Pharmaceuticals-B (02257.HK) decreased by 8.27%, with a price of HKD 8.32 [1] - Hengrui Medicine-B (02142.HK) saw a decline of 7.29%, priced at HKD 12.46 [1] - Rongchang Biopharmaceutical (09995.HK) dropped by 4.87%, now at HKD 75.15 [1]

Group 1 - The pharmaceutical sector is experiencing a general decline, with notable drops in stock prices for companies such as Genscript Biotech (down 11.02% to HKD 12.92), Sanofi (down 8.27% to HKD 8.32), and others [1] - Haitong International's research report indicates that the recent pullback in the pharmaceutical sector is primarily due to seasonal factors affecting liquidity, particularly the year-end accounting by southbound funds [1] - The report highlights a decreasing proportion of holdings in leading pharmaceutical stocks within the Hong Kong Stock Connect, such as Innovent Biologics and China National Pharmaceutical Group [1] Group 2 - Despite the short-term challenges, the report maintains a positive long-term outlook for the innovative drug industry chain, particularly for companies with strong fundamentals and successful overseas clinical progress [1] - The focus is on companies with strong earnings certainty in internet healthcare, CXO/research services, and leading biotech and pharmaceutical firms that have established external collaborations [1]

Core Viewpoint - The pharmaceutical sector is experiencing a general decline, with significant drops in stock prices for various companies, attributed to seasonal factors affecting liquidity and southbound fund flows [1] Group 1: Market Performance - Major pharmaceutical stocks have seen substantial declines, with Gilead Sciences-B (01672) down 11.02% to HKD 12.92, Sanofi-B (02257) down 8.27% to HKD 8.32, and Hengrui Medicine-B (02142) down 7.29% to HKD 12.46 [1] - Overall, the Hong Kong pharmaceutical sector has performed weakly, influenced by seasonal factors such as year-end fund settlement [1] Group 2: Analyst Insights - Haitong International's report indicates that the pharmaceutical sector is under short-term pressure due to liquidity issues, but maintains a positive long-term outlook on the innovative drug industry chain [1] - The report highlights a continuous decline in the Hong Kong Stock Connect holdings of leading pharmaceutical stocks, such as Innovent Biologics and China National Pharmaceutical Group [1] Group 3: Long-term Opportunities - The firm expresses confidence in the long-term prospects of internet healthcare, CXO/research service leaders, and top biotech and pharmaceutical companies that have established external collaborations and are making progress in overseas clinical trials [1]

Core Viewpoint - The biotechnology sector in Hong Kong is experiencing a significant decline, with several companies facing substantial stock price drops [1] Group 1: Company Performance - Gilead Sciences (歌礼制药, 01672.HK) has seen its stock price drop by over 8% [1] - Sanofi (圣诺医药, 02257.HK) has experienced a decline of more than 6% [1] - Other companies such as BeiGene (百济神州, 06160.HK) and Innovent Biologics (复宏汉霖, 02696.HK) are also following the downward trend [1]

香港联交所最新资料显示，12月8日，董事会主席潘洪辉增持圣诺医药(02257)10万股，每股作价6.83港 元，总金额为68.3万港元。增持后最新持股数目约为1762.77万股，最新持股比例为16.44%。 ...

Group 1 - The chairman of the board, Pan Honghui, increased his stake in Sanofi Pharmaceutical (02257) by purchasing 100,000 shares at a price of HKD 6.83 per share, totaling HKD 683,000 [1] - After the purchase, the total number of shares held by Pan Honghui is approximately 17.6277 million, representing a holding percentage of 16.44% [1]

Core Viewpoint - The announcement highlights the confidence of the company's executive director and chairman, Pan Honghui, in the overall development and potential growth of the company, as evidenced by his recent share purchase [1] Group 1: Share Purchase Details - Pan Honghui purchased a total of 100,000 ordinary shares of the company at an average price of approximately HKD 6.83 per share, amounting to a total cost of about HKD 683,000 [1] - Following this purchase, Pan holds a total of 17,627,696 shares, representing 16.44% of the company's total issued share capital as of the announcement date [1] Group 2: Future Intentions - Pan Honghui has indicated that he may consider further increasing his stake in the company at an appropriate time, in compliance with applicable laws and regulations [1]

Core Viewpoint - The company announced that its Executive Director and Chairman, Dr. Pan Honghui, purchased 100,000 shares at an average price of approximately HKD 6.83 per share, totaling around HKD 683,000, indicating confidence in the company's growth prospects [1] Group 1: Share Purchase Details - Dr. Pan acquired 100,000 ordinary shares in the open market at an average price of approximately HKD 6.83 per share [1] - The total cost of the share purchase was approximately HKD 683,000 [1] - Following the purchase, Dr. Pan holds a total of 17,627,696 shares, representing 16.44% of the company's issued share capital as of the announcement date [1] Group 2: Future Intentions - Dr. Pan expressed confidence in the overall development prospects and potential growth of the group [1] - He does not rule out the possibility of further increasing his shareholding in the company at an appropriate time, subject to applicable laws and regulations [1]

Core Viewpoint - Dr. Pan Honghui, the Executive Director and Chairman of Sanofi Pharmaceutical-B (02257), has purchased 100,000 shares of the company at an average price of approximately HKD 6.83 per share, totaling around HKD 683,000, indicating confidence in the company's growth prospects [1] Summary by Relevant Sections - **Share Purchase Details** - Dr. Pan acquired 100,000 shares at an average price of HKD 6.83 per share, amounting to HKD 683,000 [1] - Following the purchase, Dr. Pan holds a total of 17,627,696 shares, representing 16.44% of the company's issued share capital as of the announcement date [1] - **Outlook and Future Intentions** - Dr. Pan expressed strong confidence in the overall development prospects and potential growth of the group [1] - He does not rule out the possibility of further increasing his shareholding in the company at an appropriate time, in compliance with applicable laws and regulations [1]